AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with limited options.

AbbVie’s shares trade at US$218.63 after a 10.59% 1 month share price return, even though the stock is still down 4.66% year to date. The 1 year total shareholder return of 21.62% points to stronger underlying momentum building over time.

If this kind of healthcare progress interests you, it could be a good moment to scan beyond AbbVie and check out 35 healthcare AI stocks

With AbbVie trading at US$218.63 and currently estimated to be at a 48% discount to intrinsic value, along with a 16% gap to the average analyst target, is this a clear sign of undervaluation or is the market already accounting for future growth?

Most Popular Narrative: 12.3% Undervalued

At a last close of $218.63 against a most followed fair value estimate of about $249, the leading narrative sees AbbVie trading below its modeled worth, with that view hinging heavily on execution in immunology and neuroscience.

Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high-need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top-line revenue growth and mitigate the impact of Humira's LOE.

Curious what kind of revenue trajectory, margin uplift and future earnings multiple are baked into that fair value, and how much depends on a handful of flagship drugs? The narrative lays out a detailed earnings path, the assumed profitability reset and the valuation multiple it thinks the market could settle on, all tied to how convincingly AbbVie turns its pipeline into long term cash flows.

Result: Fair Value of $249.43 (UNDERVALUED)

However, this depends on risks such as tougher drug pricing rules and heavy dependence on a few key immunology and neuroscience products, which could still undermine those assumptions.

Another View: Earnings Multiple Sends A Different Signal

That discounted cash flow view points to AbbVie trading below estimated fair value, but the earnings multiple tells a different story. At a P/E of 107.4x versus 16.4x for the US Biotechs industry and 20.5x for peers, and a fair ratio of 37x, the stock screens as expensive rather than cheap. For you, the question is whether that gap reflects real quality or simply raises the bar for future delivery.

Next Steps

With such a mixed set of signals on value, risk and momentum, it makes sense to check the underlying data yourself and then quickly decide how it all stacks up for your portfolio using 2 key rewards and 5 important warning signs

Looking for more investment ideas?

If you stop with just one stock today, you may miss opportunities that fit your goals even better, so use the screener to keep your options open.

• Pinpoint value, and see which companies combine quality fundamentals with attractive prices through 46 high quality undervalued stocks.
• Strengthen your portfolio’s foundations by focusing on financially robust businesses using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot under-the-radar opportunities before the crowd by scanning the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.